This is a preview of subscription content, log in via an institution to check access.
Author information
Authors and Affiliations
Additional information
Received: 9 December 1996 / Accepted: 28 October 1997
Rights and permissions
About this article
Cite this article
Henze, G., Borgmann, A., von Stackelberg, A. et al. Immunotherapy of acute lymphoblastic leukemia by vaccination with autologous leukemic cells transfected with a cDNA expression plasmid coding for an allogeneic HLA class I antigen combined with interleukin-2 treatment. J Mol Med 76, 215–221 (1998). https://doi.org/10.1007/s001090050211
Issue Date:
DOI: https://doi.org/10.1007/s001090050211
- Abbreviations ALL Acute lymphoblastic leukemia
- BMT Bone marrow transplantation
- CTL Cytotoxic T-lymphocytes
- IL Interleukin
- MHC Major histocompatibility
- MRD Minimal residual diseaseIntroductionObjective
- The purpose of this protocol is to induce a specific cellular immune reaction after autologous bone marrow transplantation (BMT) by vaccination with human leukocyte antigen (HLA) B13 transfected autologous leukemic cells in children with high-risk relapse of acute lymphoblastic leukemia (ALL). Specific cytotoxic T-lymphocytes (CTL) will be expanded in vivo by low-dose interleukin-2 (IL-2). The expression vector used is the pcDNA3 HLA-B13 plasmid
- driven by a cytomegalovirus promoter. Leukemic cells are transfected by electroporation/ballistomagnetic transfer.